RxDoctor Payments Data

Janet Osayamwen

Nurse Practitioner · Hainesport, NJNPI 1154527430

Payments from drug & device makers

$1,633in general payments, 2019–2025

Across 72 payments — averaging $22.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$243
  • Bayer$203
  • AbbVie$201
  • Alkermes, Inc.$154
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$125
  • Lilly USA, LLC$108
  • plus $598 from 17 others

What the payments were for

  • Food & beverage$1,633100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,633 in reported general payments places this provider in the 85th percentile of 2,138 nurse practitioner providers in New Jersey.

See all nurse practitioner providers in New Jersey

Medicare billing

Part B allowed, 2024
$47,513
Medicare patients
245
Services billed
428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban47$34,419
JardianceEmpagliflozin19$25,559
OzempicSemaglutide22$21,088
JanuviaSitagliptin Phosphate15$14,973
LinzessLinaclotide25$14,882
Metformin Hcl116$14,017
TrulicityDulaglutide13$12,501
GemtesaVibegron13$6,347
InvokanaCanagliflozin11$6,223
Advair HfaFluticasone Propion/Salmeterol12$3,613
Albuterol Sulfate HfaAlbuterol Sulfate152$3,356
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$2,498
Insulin Lispro Kwikpen U-100Insulin Lispro15$2,330
Atorvastatin Calcium296$2,056
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$1,634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$34,41947 claims
Boehringer IngelheimJardiance$39$25,55919 claims
MerckJanuvia$78$14,97315 claims
AbbVieLinzess$201$14,88225 claims
Lilly USA, LLCTrulicity, Humulin 70-30$108$13,00926 claims
Johnson & JohnsonInvokana$14$6,22311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,138 nurse practitioner providers in New Jersey.

Other nurse practitioner in Hainesport

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →